Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: okuda h. Oncologist. 2022 May 6;27(5):340-e374. doi: 10.1093/oncolo/oyab062. Oncologist. 2022. PMID: 35303078 Free PMC article. Clinical Trial.
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Kobayashi Y, et al. Among authors: okuda h. Future Oncol. 2015;11(4):617-27. doi: 10.2217/fon.14.251. Future Oncol. 2015. PMID: 25686117 Clinical Trial.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: okuda h. Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086. Oncologist. 2022. PMID: 35579511 Free PMC article. Clinical Trial.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Miura Y, et al. Among authors: okuda h. Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11. Gastric Cancer. 2018. PMID: 28497176 Clinical Trial.
An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect).
Matsuoka H, Ogata Y, Nakamura M, Shibata Y, Munemoto Y, Bando H, Nishijima K, Okuda H, Terada I, Shiroiwa T, Kishimoto J, Maeda K. Matsuoka H, et al. Among authors: okuda h. J Anus Rectum Colon. 2020 Apr 28;4(2):79-84. doi: 10.23922/jarc.2019-020. eCollection 2020. J Anus Rectum Colon. 2020. PMID: 32346646 Free PMC article.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T. Makiyama A, et al. Among authors: okuda h. Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20. Gastric Cancer. 2018. PMID: 29353332 Clinical Trial.
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: okuda h. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
Saito M, Yamashita K, Arimura Y, Kaneto H, Okuda H, Nojima M, Hagiwara T, Suzuki K, Adachi T, Goto A, Nakachi K, Yawata A, Yoshimoto M, Tanuma T, Adachi Y, Yamaoka S, Mizukoshi T, Kawayama M, Hamamoto Y, Shinomura Y. Saito M, et al. Among authors: okuda h. Acta Oncol. 2016;55(3):309-17. doi: 10.3109/0284186X.2015.1107189. Epub 2016 Jan 12. Acta Oncol. 2016. PMID: 26757197
Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A, Sukawa Y, Igarashi H, Onodera K, Aoki Y, Suzuki K, Yonezawa K, Yawata A, Kobayashi T, Kaneto H, Shimizu H, Wakasugi H, Matsunaga Y, Itoh M, Okuda H, Arimura Y, Shinomura Y. Goto A, et al. Among authors: okuda h. Gan To Kagaku Ryoho. 2011 Sep;38(9):1461-6. Gan To Kagaku Ryoho. 2011. PMID: 21945893
1,072 results